United Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
Phase 4
Completed
- Conditions
- Pulmonary Arterial HypertensionPulmonary Hypertension
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT00058929
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸The Rush Heart Institute Center for Pulmonary Heart Disease, Chicago, Illinois, United States
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
Phase 3
Completed
- Conditions
- Pulmonary Hypertension
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT00004497
- Locations
- 🇺🇸
Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath